A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

September 8, 2026 updated by: EMD Serono Research & Development Institute, Inc.

A Randomized, Open Label, 3-arm Phase 3 Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

This study aims to address the unmet medical need of participants with metastatic colorectal cancer (mCRC) who have previously been treated with irinotecan, oxaliplatin, a fluoropyrimidine, and bevacizumab, by demonstrating an overall survival prolongation with precemtabart tocentecan (Precem-TcT) as single agent or Precem-TcT in combination with bevacizumab compared to trifluoride/tipiracil (FTD-TPI) plus bevacizumab.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

1020

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Argentina
      • Ciudad Autonoma Buenos Aires, Argentina, C1417DTB
        • Recruiting
        • Investigaciones Clinicas Moleculares Icm
      • San Juan, Argentina, 5400
        • Recruiting
        • Centro Oncológico de Excelencia
      • San Miguel de Tucumán, Argentina, T4000AXL
        • Recruiting
        • Centro de Investigaciones Médicas Tucuman
    • Santa Fe Province
      • Rosario, Santa Fe Province, Argentina, S2000KZE
        • Recruiting
        • Instituto de Oncologia de Rosario
  • Australia
    • New South Wales
      • St Leonards, New South Wales, Australia, 2065
        • Recruiting
        • GenesisCare North Shore (Oncology)
    • Queensland
      • Chermside, Queensland, Australia, 4032
        • Recruiting
        • Icon Cancer Centre Chermside
      • South Brisbane, Queensland, Australia, 4101
        • Recruiting
        • Mater Misericordiae Ltd - PARENT
    • South Australia
      • Bedford Park, South Australia, Australia, 5042
        • Recruiting
        • Flinders Medical Centre
  • Austria
      • Salzburg, Austria, 5020
        • Recruiting
        • LKH - Universitätsklinikum der PMU Salzburg - Innere Med III/Hämatologie und Onkologie
  • Belgium
      • Brussels, Belgium, 1200
        • Recruiting
        • Cliniques Universitaires Saint-Luc - STL
      • Charleroi, Belgium, 6000
        • Recruiting
        • Grand Hospital de Charleroi - PARENT
  • Canada
    • Ontario
      • Ottawa, Ontario, Canada, K1H 8L6
        • Recruiting
        • The Ottawa Hospital Cancer Centre
      • Toronto, Ontario, Canada, M5G 2M9
        • Recruiting
        • University Health Network - Princess Margaret Cancer Centre
  • China
    • Guangdong
      • Guangzhou, Guangdong, China, 510060
        • Recruiting
        • Sun Yat-sen University Cancer Center
    • Guangxi Zhuang
      • Nanning, Guangxi Zhuang, China, 530021
        • Recruiting
        • Guangxi Medical University Cancer Hospital
    • Hubei
      • Wuhan, Hubei, China, 430060
        • Recruiting
        • Union Hospital Tongji Medical College Huazhong University Of Science And Technology
    • Jiangsu
      • Nanjing, Jiangsu, China, 210029
        • Recruiting
        • Jiangsu Province Hospital
    • Sichuan
      • Chengdu, Sichuan, China, 610041
        • Recruiting
        • Sichuan Cancer Hospital
    • Zhejiang
      • Hangzhou, Zhejiang, China, 310000
        • Recruiting
        • The Second Affiliated Hospital of Zhejiang University School of Medicine - 300173725
  • France
      • Paris, France, 75013
        • Recruiting
        • Groupe Hospitalier Pitie-Salpetriere - Service Hépato-Gastro-Entérologie
    • Nord
      • Lille, Nord, France, 59037
        • Recruiting
        • Hopital Claude Huriez - CHU Lille - service d'oncologie medicale
    • Pays de la Loire Region
      • Saint Priest En Jarez, Pays de la Loire Region, France, 42270
        • Recruiting
        • CHU Saint Etienne - Hôpital Nord - Service de Gastro-Entérologie et Hépatologie
    • Rhone
      • Lyon, Rhone, France, 69008
        • Recruiting
        • Centre Leon Berard - Service d'Oncologie Medicale
  • Germany
    • Hesse
      • Frankfurt am Main, Hesse, Germany, 60488
        • Recruiting
        • Krankenhaus Nordwest GmbH - Neurologische Klinik
  • Hong Kong
      • Hong Kong, Hong Kong, 00000
        • Recruiting
        • The Chinese University of Hong Kong (CUHK) - Prince of Wales Hospital (PWH)
  • Japan
    • Fukuoka
      • Fukuoka, Fukuoka, Japan, 811-1395
        • Recruiting
        • NHO Kyushu Cancer Center - 300175822
    • Kanagawa
      • Yokohama, Kanagawa, Japan, 241-8515
        • Recruiting
        • Kanagawa Cancer Center - Dept of Gastroenterology
    • Osaka
      • Sakai-shi, Osaka, Japan, 590-0197
        • Recruiting
        • Kindai University Hospital
    • Saitama
      • Kitaadachi-gun, Saitama, Japan, 362-0806
        • Recruiting
        • Saitama Cancer Center - 300175812
    • Tokyo-To
      • Chūōku, Tokyo-To, Japan, 104-0045
        • Recruiting
        • National Cancer Center Hospital
      • Kōtoku, Tokyo-To, Japan, 135-8550
        • Recruiting
        • Cancer Institute Hospital of JFCR
  • Poland
      • Krakow, Poland, 31-501
        • Recruiting
        • SP ZOZ Szpital Uniwersytecki w Krakowie - Dept of Clinical Oncology and Oncology Clinic
  • South Korea
      • Seoul, South Korea, 03080
        • Recruiting
        • Seoul National University Hospital
      • Seoul, South Korea, 06351
        • Recruiting
        • Samsung Medical Center
      • Seoul, South Korea, 08308
        • Recruiting
        • Korea University Guro Hospital
      • Seoul, South Korea, 138-736
        • Recruiting
        • Asan Medical Center
      • Seoul, South Korea, 03722
        • Recruiting
        • Severance Hospital, Yonsei University Health System - Division of Infectious Diseases
      • Seoul, South Korea, 06591
        • Recruiting
        • The Catholic University of Korea, Seoul St. Maryâ
    • Gyeonggi-do
      • Goyang-si, Gyeonggi-do, South Korea, 10408
        • Recruiting
        • National Cancer Center
      • Seongnam-si, Gyeonggi-do, South Korea, 13620
        • Recruiting
        • Seoul National University Bundang Hospital
    • Gyeongsangnam-do
      • Daegu, Gyeongsangnam-do, South Korea, 700-721
        • Recruiting
        • Kyungpook National University Chilgok Hospital
  • Spain
      • Madrid, Spain, 28034
        • Recruiting
        • Hospital Universitario Ramon y Cajal - Servicio de Oncologia
  • Taiwan
      • Kaohsiung City, Taiwan, 807
        • Recruiting
        • Kaohsiung Medical University Chung-Ho Memorial Hospital
      • Taichung, Taiwan, 40447
        • Recruiting
        • China Medical University Hospital
      • Taipei, Taiwan, 11217
        • Recruiting
        • Taipei Veterans General Hospital
  • United Kingdom
    • Grampian Region
      • Aberdeen, Grampian Region, United Kingdom, AB25 2ZN
        • Recruiting
        • Aberdeen Royal Infirmary - Dept of Oncology
    • Great Manchester
      • Manchester, Great Manchester, United Kingdom, M20 4BX
        • Recruiting
        • The Christie Hospital - Dept of Oncology
  • United States
    • Colorado
      • Lone Tree, Colorado, United States, 80124
        • Recruiting
        • Rocky Mountain Cancer Centers, LLP- Aurora
    • Florida
      • Fort Myers, Florida, United States, 33901
        • Recruiting
        • Florida Cancer Specialists-Broadway
      • St. Petersburg, Florida, United States, 33701-4553
        • Recruiting
        • Florida Cancer Specialists - St. Petersburg Bayfront
      • West Palm Beach, Florida, United States, 33401
        • Recruiting
        • Florida Cancer Specialists East - FCS EAST - West Palm Beach
    • Illinois
      • Arlington Heights, Illinois, United States, 60005
        • Recruiting
        • Illinois Cancer Specialists
      • Peoria, Illinois, United States, 61615-7822
        • Recruiting
        • Illinois CancerCare PC
      • Springfield, Illinois, United States, 62702
        • Recruiting
        • Springfield Clinic
    • Michigan
      • Sterling Heights, Michigan, United States, 48098
        • Recruiting
        • Profound Research LLC at Cancer and Leukemia Center
    • Minnesota
      • Saint Louis Park, Minnesota, United States, 55416
        • Recruiting
        • Minnesota Oncology Hematology, P.A.
    • Missouri
      • Columbia, Missouri, United States, 65201
        • Recruiting
        • Missouri Cancer Associates - 150518964
    • New York
      • White Plains, New York, United States, 10601
        • Recruiting
        • White Plains Hospital Medical and Wellness PRIME
    • Tennessee
      • Nashville, Tennessee, United States, 37203
        • Recruiting
        • SCRI Oncology Partners
    • Texas
      • Abilene, Texas, United States, 79606
        • Recruiting
        • Texas Oncology, P.A. - Abilene - 300210366
      • Austin, Texas, United States, 78745
        • Recruiting
        • Texas Oncology-South Austin
      • Bedford, Texas, United States, 75246
        • Recruiting
        • Texas Oncology DFW
      • San Antonio, Texas, United States, 78240
        • Recruiting
        • Texas Oncology- San Antonio
      • Tyler, Texas, United States, 75702
        • Recruiting
        • Texas Oncology, P.A. - Tyler
    • Virginia
      • Newport News, Virginia, United States, 23606
        • Recruiting
        • Virginia Oncology Associates
      • Roanoke, Virginia, United States, 24014-2419
        • Recruiting
        • Blue Ridge Cancer Care - 300202915

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Participants with documented histopathological diagnosis of metastatic colorectal cancer, who were intolerant to, or whose disease was refractory to, or progressed after standard systemic therapies and no more than 2 previous systemic treatment regimens in the metastatic setting.
  • Participants must have received and progressed on no more than 2 previous systemic treatment regimens in the metastatic setting
  • Eastern Cooperative Oncology Group (ECOG) performance status less than equal to 1
  • Participants must be able to swallow oral tablets, and to comply with the study requirements for all scheduled evaluations
  • Other protocol defined inclusion criteria may apply

Exclusion Criteria:

  • If Adverse Events related to previous therapies have not recovered to less than Grade 1 by National Cancer Institute - Common Terminology Criteria for Adverse Events version 6.0
  • Participant has a history of additional malignancy within 3 years before randomization
  • Participants with known brain metastases
  • Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months prior to randomization
  • Participants with ileus of more than Grade 1, or chronic inflammatory bowel disease (example ulcerative colitis, Crohn's disease) and/or bowel obstruction, or participants with chronic gastrointestinal disorders that, in the Investigator's opinion, might significantly interfere with proper absorption of the study treatments
  • Other protocol defined exclusion criteria may apply

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Arm 1: Precemtabart tocentecan (Precem-TcT) Monotherapy
Drug: Precemtabart tocentecan
Precem-TcT, administered, once every 3 weeks intravenously, on Day 1 of each 21-day cycle.
Other Names:
  • Precem-TcT
Experimental: Arm 2: Precem-TcT plus Bevacizumab
Drug: Precemtabart tocentecan
Precem-TcT, administered, once every 3 weeks intravenously, on Day 1 of each 21-day cycle.
Other Names:
  • Precem-TcT
Drug: Bevacizumab
Bevacizumab, administered intravenously every 3 weeks on Day 1 of each 21-day cycle or every 2 weeks on Day 1 and Day 15 of each 28-day cycle.
Active Comparator: Arm 3: Trifluridine/Tipiracil (FTD-TPI) plus Bevacizumab
Drug: Bevacizumab
Bevacizumab, administered intravenously every 3 weeks on Day 1 of each 21-day cycle or every 2 weeks on Day 1 and Day 15 of each 28-day cycle.
Drug: Trifluridine/Tipiracil (FTD-TPI)
FTD-TPI, tablet, administered orally twice daily, on Days 1 to 5 and Days 8 to 12 of each 28-day cycle.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Arm 1, 2 and 3: Overall Survival
Time Frame: Time from date of randomization to death, assessed approximately up to average of 19 months
Time from date of randomization to death, assessed approximately up to average of 19 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Arm 1 and Arm 2: Overall Survival
Time Frame: Time from date of randomization to death, assessed approximately up to average of 19 months
Time from date of randomization to death, assessed approximately up to average of 19 months
Progression Free Survival (PFS)
Time Frame: Time from randomization to the first occurrence of disease progression or death, whichever occurs first (assessed up to average of 19 months)
Time from randomization to the first occurrence of disease progression or death, whichever occurs first (assessed up to average of 19 months)
Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Investigator
Time Frame: Up to average of 19 months
Up to average of 19 months
Duration of Response as Assessed by Investigator
Time Frame: Time from first documentation of objective response to PD or death (assessed up to average of 19 months)
Time from first documentation of objective response to PD or death (assessed up to average of 19 months)
Number of Participants with Adverse Events (AEs) and Treatment Related Adverse Events
Time Frame: Up to average of 19 months
Up to average of 19 months
Observed Concentration at End of Infusion (CEOI) Period
Time Frame: At end of infusion on Cycle 1 Day 1 and Cycle 3 Day 1 (Arm 1 and Arm 2 only; each cycle is for 21 days)
At end of infusion on Cycle 1 Day 1 and Cycle 3 Day 1 (Arm 1 and Arm 2 only; each cycle is for 21 days)
Concentration Observed at the end of a Dosing Interval Immediately Before next Dosing (Ctrough)
Time Frame: At end of dosing interval on Cycle1Day1,Cycle2Day1,Cycle3Day1,Cycle4Day1, Cycle5Day1,Cycle6Day1,Cycle7Day1 until treatment discontinuation(assessed up to average of 19months (Arm 1 and Arm 2 only; each cycle is for 21 days)
At end of dosing interval on Cycle1Day1,Cycle2Day1,Cycle3Day1,Cycle4Day1, Cycle5Day1,Cycle6Day1,Cycle7Day1 until treatment discontinuation(assessed up to average of 19months (Arm 1 and Arm 2 only; each cycle is for 21 days)
Number of Participants with Anti-Drug Antibody as measured by ADA assay
Time Frame: Predose(-4to0 hours)on Cycle1Day1,Cycle2 Day1,Cycle 3Day1,Cycle4Day1, Cycle8Day1;thereafter every 4cycles until treatment discontinuation(assessed up to average of 19 months) (Arm 1 and Arm 2 only; each cycle is for 21 days)
Predose(-4to0 hours)on Cycle1Day1,Cycle2 Day1,Cycle 3Day1,Cycle4Day1, Cycle8Day1;thereafter every 4cycles until treatment discontinuation(assessed up to average of 19 months) (Arm 1 and Arm 2 only; each cycle is for 21 days)
Change from Baseline in Global Health Status, Physical, and Role Functioning Subscale Scores of European Organization for research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)
Time Frame: Baseline, Cycle 1 Day 1 and Day 1 of every new cycle until treatment discontinuation (assessed up to average of 19 months).
EORTC QLQ-C30 is a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, role, cognitive, emotional, social), and 9 symptom scales/items (Fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact. The EORTC QLQ-C30 GHS/QoL score ranges from 0 to 100; High score indicates better GHS/QoL. Score 0 represents: very poor physical condition and QoL. Score 100 represents: excellent overall physical condition and QoL.
Baseline, Cycle 1 Day 1 and Day 1 of every new cycle until treatment discontinuation (assessed up to average of 19 months).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

EMD Serono Research & Development Institute, Inc.

Collaborators

Merck KGaA, Darmstadt, Germany

Investigators

  • Study Director: Medical Responsible, EMD Serono Research & Development Institute, Inc.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 6, 2026

Primary Completion (Estimated)

October 16, 2029

Study Completion (Estimated)

October 16, 2029

Study Registration Dates

First Submitted

April 16, 2026

First Submitted That Met QC Criteria

April 16, 2026

First Posted (Actual)

April 24, 2026

Study Record Updates

Last Update Posted (Actual)

September 9, 2026

Last Update Submitted That Met QC Criteria

September 8, 2026

Last Verified

August 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MS914001_0002
  • 2025 (U.S. NIH Grant/Contract: Faculty of Social Sciences Scientific Grant at the University of Gdańsk)
  • 2025-524648-37-00 (Ctis)
  • CTR20262356 (Other Identifier: ChinaDrugTrials.org.cn)
  • jRCT2031260267 (Other Identifier: JRCT (Japan))

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

IPD supporting publicly available results will be evaluated for sharing.

IPD Sharing Time Frame

IPD from completed trials will be publicly available within 6 months after all of the following events:

  • Approval of a product/new indication by major authorities (FDA, EMA, PMDA if requested) with no pending submissions
  • Public results via primary manuscript or trial registry disclosure
  • Legal authority to share data
  • Privacy protections are in place If approval is not sought or development is globally discontinued, data will be publicly available within 18 months after global trial completion. Further information on how to request data can be found on our website bit.ly/IPD21

IPD Sharing Access Criteria

Qualified researchers may propose access to IPD from sponsored trials via https://vivli.org/members/ourmembers/.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ANALYTIC_CODE
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe